Carisbamate (DrugBank: Carisbamate)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
144 | Lennox-Gastaut syndrome | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04062981 (ClinicalTrials.gov) | May 3, 2019 | 30/5/2019 | Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome | Phase 1, Open-Label Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome | Lennox Gastaut Syndrome | Drug: Carisbamate | SK Life Science, Inc. | NULL | Recruiting | 2 Years | N/A | All | 30 | Phase 1 | United States |
2 | NCT03731715 (ClinicalTrials.gov) | February 7, 2019 | 16/10/2018 | Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome | Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome | Lennox Gastaut Syndrome | Drug: Carisbamate | SK Life Science, Inc. | NULL | Recruiting | 2 Years | N/A | All | 24 | Phase 1 | United States |